TA Associates invests in Taiwanese tea brand Gong cha

pallavi123- November 27, 2019 0

Taiwanese tea brand Gong cha Group has closed an undisclosed investment from global growth private equity firm TA Associates. Established in 2006, Gong cha offers ... Read More

Final turbine installed at 120MW Formosa 1 offshore wind farm phase 2

Soujanya- October 20, 2019 0

Ørsted said that the installation of the final turbine of the 120MW Formosa 1 offshore wind farm phase 2 in Taiwan has been completed. The ... Read More

Rinchem to open hazardous materials warehouse in Taiwan

Pallavi Madhiraju- September 28, 2019 0

Rinchem said that it will open a new hazardous materials warehouse in Taiwan to be located in Tainan, as per the latest chemical industry news. ... Read More

Formosa 1 offshore wind farm : Jan De Nul wraps up installation of foundations for phase 2

Pallavi Madhiraju- September 14, 2019 0

Jan De Nul Group has wrapped up the installation of all the 20 foundations for the second phase of the 120MW Formosa 1 offshore wind ... Read More

Phase 2 of Formosa 1 offshore wind farm in Taiwan produces first power

Soujanya- September 11, 2019 0

Danish energy company Ørsted and its partners have generated first power from the second phase of the 128MW Formosa 1 offshore wind farm located in ... Read More

Changhua Windfarm Phase 1 : Heerema bags contract for installation of jacket foundations

Pallavi Madhiraju- July 27, 2019 0

Jan de Nul’s Taiwan branch has selected Heerema Marine Contractors to install 21 jacket foundations (4 legged) for the 110MW Changhua Windfarm Phase 1 offshore ... Read More

InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal

pharmanewsdaily- December 31, 2018 0

In a significant development within the pharmaceutical industry, Shanghai-based InventisBio has entered into a strategic partnership with Betta Pharmaceuticals Co., Ltd. to co-develop the promising ... Read More

TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients

pharmanewsdaily- October 21, 2018 0

TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for ... Read More